- Home
- DTIL vs ALVR Comparison
DTIL vs ALVR Comparison
Compare DTIL & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- ALVR
- Stock Information
- Founded
- DTIL 2006
- ALVR 2013
- Country
- DTIL United States
- ALVR United States
- Employees
- DTIL N/A
- ALVR N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DTIL Health Care
- ALVR Health Care
- Exchange
- DTIL Nasdaq
- ALVR Nasdaq
- Market Cap
- DTIL 43.3M
- ALVR 48.8M
- IPO Year
- DTIL 2019
- ALVR 2020
- Fundamental
- Price
- DTIL $5.93
- ALVR $9.63
- Analyst Decision
- DTIL Strong Buy
- ALVR
- Analyst Count
- DTIL 3
- ALVR 0
- Target Price
- DTIL $37.67
- ALVR N/A
- AVG Volume (30 Days)
- DTIL 123.5K
- ALVR 22.1K
- Earning Date
- DTIL 03-26-2025
- ALVR 03-14-2025
- Dividend Yield
- DTIL N/A
- ALVR N/A
- EPS Growth
- DTIL N/A
- ALVR N/A
- EPS
- DTIL 1.45
- ALVR N/A
- Revenue
- DTIL $75,096,000.00
- ALVR N/A
- Revenue This Year
- DTIL $51.35
- ALVR N/A
- Revenue Next Year
- DTIL N/A
- ALVR N/A
- P/E Ratio
- DTIL $4.07
- ALVR N/A
- Revenue Growth
- DTIL 43.62
- ALVR N/A
- 52 Week Low
- DTIL $3.61
- ALVR $7.96
- 52 Week High
- DTIL $19.43
- ALVR $24.15
- Technical
- Relative Strength Index (RSI)
- DTIL 63.88
- ALVR 45.63
- Support Level
- DTIL $4.60
- ALVR $9.55
- Resistance Level
- DTIL $5.23
- ALVR $10.41
- Average True Range (ATR)
- DTIL 0.36
- ALVR 0.44
- MACD
- DTIL 0.13
- ALVR 0.05
- Stochastic Oscillator
- DTIL 88.67
- ALVR 22.77
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.